논문발표

인트론바이오 다수의 특허확보를 통한 기술경쟁력 강화는 물론, 해외 유수의 학회지에 관련 기술개발결과를 발표해 오고 있으며, 이또한 “글로벌 R&BD 그룹”의 위상 강화에 필요한 노력입니다.

it is iNtRON.
29
No. 제목
29 Effects of Phage Endolysin SAL200 Combined with Antibiotics on Staphylococcus aureus Infection. Antimicrob Agents Chemother. 62(10): e00731-18, 2018
28 Evaluation of the broad-spectrum lytic capability of bacteriophage cocktails against various Salmonella serovars and their effects on weaned pigs infected with Salmonella Typhimurium. J Vet Med Sci. 80(6): 851-860, 2018
27 Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis. Scientific Reports. 8(1): 18, 2018
26 Simultaneous RNA-seq based transcriptional profiling of intracellular Brucella abortus and B. abortus-infected murine macrophages. Microbial Pathogenesis. 113: 57-67, 2017
25 Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers. Antimicrob Agents Chemother. 2017 May 24;61(6).
24 Evaluating the effectiveness of Streptococcus parauberis bacteriophage Str-PAP-1 as an environmentally friendly alternative to antibiotics for aquaculture Aquaculture., 468(Part 1):464-470, 2017
23 Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period Clin. Exp. Pharmacol. Physiol. 43(10): 1013-1016, 2016
22 The herbal-derived honokiol and magnolol enhances immune response to infection with methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA) Appl. Microbiol. Biotechnol. 99(10): 4387-4396, 2015
21 이유자돈에서 Salmonella Typhimurium 감염에 대한 박테리오파지의 방어 효능 한국가축위생학회지 37(1), 35-43, 2014
20 Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient Antimicrob. Agents Chemother. 58(4), 2084-2088, 2014
1 2 3 4